Protara Therapeutics Files 8-K: Material Agreement
Ticker: TARA · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1359931
| Field | Detail |
|---|---|
| Company | Protara Therapeutics, Inc. (TARA) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $6.25, $6.249, $100 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Protara Therapeutics signed a big deal on Dec 9th, 8-K filed.
AI Summary
On December 9, 2024, Protara Therapeutics, Inc. entered into a material definitive agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This filing indicates a significant new agreement for Protara Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, requiring careful evaluation of the terms and potential impact.
Key Players & Entities
- Protara Therapeutics, Inc. (company) — Registrant
- December 9, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Protara Therapeutics, Inc. enter into?
The filing states that Protara Therapeutics, Inc. entered into a material definitive agreement on December 9, 2024, but the specific details of the agreement are not provided in this summary.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
Regulation FD Disclosure ensures that material non-public information is disseminated to all investors simultaneously, preventing selective disclosure.
What are the previous names of Protara Therapeutics, Inc.?
Protara Therapeutics, Inc. was formerly known as ArTara Therapeutics, Inc. (name change effective January 10, 2020) and before that, PROTEON THERAPEUTICS INC (name change effective April 20, 2006).
Where is Protara Therapeutics, Inc. headquartered?
Protara Therapeutics, Inc. is headquartered at 345 Park Avenue South, Third Floor, New York, NY 10010.
What is the SIC code for Protara Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Protara Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,698 words · 7 min read · ~6 pages · Grade level 11.8 · Accepted 2024-12-11 16:19:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Capital M
- $6.25 — price to the public in the Offering was $6.25 per Share and $6.249 per Pre-Funded War
- $6.249 — in the Offering was $6.25 per Share and $6.249 per Pre-Funded Warrant, which is the pr
- $100 m — fering are expected to be approximately $100 million, before deducting fees to the und
Filing Documents
- ea0224389-8k_protara.htm (8-K) — 50KB
- ea022438901ex1-1_protara.htm (EX-1.1) — 235KB
- ea022438901ex4-1_protara.htm (EX-4.1) — 83KB
- ea022438901ex5-1_protara.htm (EX-5.1) — 7KB
- ea022438901ex99-1_protara.htm (EX-99.1) — 8KB
- ea022438901ex99-2_protara.htm (EX-99.2) — 8KB
- ea022438901ex99-3_protara.htm (EX-99.3) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- ex99-2_001.jpg (GRAPHIC) — 2KB
- ex99-3_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-107906.txt ( ) — 684KB
- tara-20241209.xsd (EX-101.SCH) — 3KB
- tara-20241209_lab.xml (EX-101.LAB) — 33KB
- tara-20241209_pre.xml (EX-101.PRE) — 22KB
- ea0224389-8k_protara_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2024 Protara Therapeutics, Inc. By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 3